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The  present  investigation  concerns  with  the  development  of  controlled  release  tablets  of lamivudine  using
acetylated  moth  bean  starch.  The  acetylated  starch  was  synthesized  with  acetic  anhydride  in pyridine
medium.  The  acetylated  moth  bean  starch  was  tested  for acute  toxicity  and  drug–excipient  compatibility
study.  The  formulations  were  evaluated  for physical  characteristics  like hardness,  friability,  % drug  contentey words:
amivudine
ontrolled release tablet
cetylation
oth bean starch
and  weight  variations.  The  in  vitro  release  study  showed  that  the  optimized  formulation  exhibited  highest
correlation  (R)  value  in  case  of Higuchi  kinetic  model  and  the release  mechanism  study  proved  that  the
formulation  showed  a  combination  of  diffusion  and erosion  process.  There  was  a signiﬁcant  difference
in  the  pharmacokinetic  parameters  (Tmax, Cmax,  AUC,  Vd, T1/2 and  MDT)  of the  optimized  formulation  as
compared  to the marketed  conventional  tablet  Lamivir®, which  proved  controlled  release potential  of
acetylated  moth  bean  starch.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license. . Introduction
In recent years, a new generation of biomaterials has been
ntroduced as tablet excipient for purpose of controlled drug
elease. Different modiﬁcation techniques, such as chemical reac-
ion, complexation reaction and grafting have been applied to alter
ative biomaterials by the process of substitution of functional
roups with other compounds. Recent efforts in drug develop-
ent resulted in a number of controlled drug delivery systems
onsisting of a drug encapsulated within a suitable polymer car-
ier or equally dispersed in a polymeric matrix [1].  Reservoir and
atrix type tablets are the most commonly used orally admin-
stered sustained release preparations. Especially matrix tablets,
hich are produced by direct compression using either hydrophilic
olymer such as natural gums, HPMC, CMC, Carbopol or hydropho-
ic polymer, like ethyl cellulose and amylodextrin, which are
elatively easy to manufacture [2].  Acetylation of starches is
n important modiﬁcation that has been applied to the native
tarches to impart thickening and known for more than a cen-
ury. In the acetylation, parts of the hydroxyl groups of the
-d-glucopyranose units have been converted by esteriﬁcation
o acetyl groups. High acetyl substituted starch with a degree
f substitution (DS) of 2–3 was of research interest because of
heir solubility in acetone and chloroform and for their thermo
lasticity [3,4]. Lamivudine (LAM) is the ﬁrst nucleoside analogue
pproved to treat chronic HBV infection and AIDS. Conventional
∗ Corresponding author. Tel.: +91 8439265825; fax: +91 373 2370323.
E-mail address: akhileshvikram@gmail.com (A.V. Singh).
141-8130 © 2012 Elsevier B.V.   
oi:10.1016/j.ijbiomac.2011.12.011
Open access under CC BY-NC-ND license. oral formulations of LAM are administered two  times a day 150 mg
each time because of its moderate half-life (t1/2 = 5–7 h). Treat-
ment of AIDS using conventional formulations of LAM is found
to have many drawbacks, such as adverse side effects resulting
from accumulation of drug in multi-dose therapy, poor patient
compliance, and high cost [5].  The aim of the present study was
to evaluate the acetylated moth bean starch as hydrophobic inert
matrix former in the formulation of controlled release tablets
of lamivudine by direct compression technique. The formulated
tablets were evaluated for various physical characteristics, in vitro
dissolution study and in vivo pharmacokinetic study in rabbit
model.
2. Materials and methods
Lamivudine (LAM) was kindly gifted by Ranbaxy Limited, Paonta
Sahib, Himachal Pradesh, India. Spray dried lactose (SDL) was
kindly donated by DMV  Fonterra excipients, the Netherlands.
Polyvinyl pyrrolidine K-30 (PVP K-30), magnesium stearate and
talc were purchased from Loba Chemie Limited, Mumbai, India. All
other chemicals used were of analytical grade and purchased from
SD Fine Chemical Limited, Mumbai, India.
Digital weighing balance (Sartorius, Germany) and Rotary ten
station tablet punching machine (Shakti Engineering Limited,
Ahmedabad, India). UV-Visible Spectrophotometer (UV-1700, Shi-
madzu, Japan), HPLC (Waters®, USA), Eight basket digital in vitro
USP dissolution apparatus (Electrolab, Mumbai, India), Monsano
hardness tester and Roche friabilator (Campbell Electronics, Mum-
bai, India) Laboratory scale stability chamber (Model TH-90 S/G,
Thermolab, Mumbai, India).
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.1. Synthesis of acetylated moth bean starch
Native moth bean starch was isolated from the wet  grinding
ethod. The dried starch ﬂakes were crushed, grounded and ﬁnally
assed through a sieve #120 (0.125 mm).  The uniform moth bean
tarch was pregelatinized by heating it with water at 70 ◦C. The
regelatinized starch was dried and sieved through mesh #60
0.251 mm).  The acetylation of 25 g pregelatinized starch was done
ith 100 g acetic anhydride in a medium of 200 g pyridine [6,7].
he reaction was carried out at varying temperature of 50–150 ◦C
nd time 1–6 h. The ﬁnal product was precipitated with ethanol ﬁl-
ered and dried in vacuum oven and passed through a sieve #60
nd stored till further study.
.2. Determination of degree of substitution (DS)
DS was determined using the method described elsewhere [8].
ccurately weighted 1.0 g of grounded sample was  added to the
queous solution of ethanol (75%). The slurry was  kept in the
ater bath for 30 min, after the slurry was cooled down an exact
mount of aqueous solution of potassium hydroxide (0.5 M,  30 mL)
as added and solution was stirred for 72 h. Indicator (phenolph-
halein) was added in excess to the alkali and was titrated with
.5 M hydrochloric acid.
Acetyl content (A%) was calculated according to the following
quation:
cetyl group (%) = (Value for blank − Value for sample) (mL)
Sampling weight (g)
× molarity of HCl × 0.043 × 100 (2)
cetyl content was used to calculate the degree of substitution,
DS), according to following equation:
S = 162 × % Acetyl group
4300 − (42 × % Acetyl group) (3)
here 162 is the molecular weight of the anhydroglucose unit, 42
s the molecular weight of replaceable acetyl group and 4300 is
he molecular weight of the acetyl group attached with 100 anhy-
roglucose unit.
.3. Acute toxicity study of acetylated moth bean starch
Healthy male and female Swiss albino mice (8 weeks) used for
he acute oral toxicity study were breed and reared at the Animal
ouse of Gayatri College of Pharmacy, Orissa. The animals were
oused in polypropylene cages and provided with bedding of clean
addy husk. The animals were acclimatized to laboratory condi-
ions for one week prior to experiment. The temperature in the
nimal house was maintained at 25 ± 2 ◦C with a relative humidity
f 30–70% and illumination cycle set to 12 h light and 12 h dark.
he mice were fed with standard laboratory pelleted feed (M/s
old Mohur Foods and Feeds Ltd., Bangalore, India). All the mice of
oth the sexes were fasted overnight before experimentation and
ere allowed to take food one hour after the experiment. Modi-
ed starch was  administered orally at a dose of 2000 mg/kg b.w. in
istilled water. The animals were observed for any mortality and
orbidity (convulsions, tremors, grip strength and pupil dilatation)
t an interval of 12 h for 14 days. This study was approved by theogical Macromolecules 50 (2012) 362– 368 363
(1)
Animal Ethical Committee of Gayatri College of Pharmacy (Regn.
No.1339/ac/10/cpcsea).
2.4. Preformulation study
2.4.1. Drug–excipient compatibility study by DSC
A differential scanning calorimetry (JADE DSC, Perkin Elmer,
USA) was  used to study the thermal analysis of drug–excipient
compatibility. Firstly, binary mixtures of lamivudine and excipients
(in 1:1 mass/mass ratio) were prepared by using physical mixture
technique. The drug–excipient mixture was scanned in the tem-
perature range of 50–220 ◦C under an atmosphere of nitrogen. The
heating rate was  20 ◦C/min and the obtained thermograms were
observed for any type of interaction.
2.4.2. Drug–excipient compatibility study by FT-IR spectroscopy
FT-IR spectra was recorded on a Bruker spectrophotome-
ter (Model – 220, Germany) using KBr discs in the range of
4000–450 cm−1. FT-IR analysis has been performed using sample
of lamivudine with various excipients and acetylated moth bean
starch at 1:1 mass/mass ratio.
2.4.3. Isothermal stress testing (IST) analysis
In isothermal stress testing [9,10] samples of drug and differ-
ent excipients were weighed directly in 5 mL  glass vials (n = 3).
After mixing on a cyclomixer for 3 min, 10% (w/w) water was
added in each of the vial. The glass vials, after teﬂon sealing, were
stored at 50 ◦C in hot air oven. Drug–excipient blends without
adding water were stored in refrigerator served as controls. The
drug–excipient blends were periodically examined for any change
in physical appearance. Samples were quantitively analysed using
UV-Vis spectrophotometer (Pharmaspec 1700, Shimadzu, Japan)
after 4 weeks of storage at above conditions.
2.5. Formulation of tablets
The lamivudine controlled release tablets were formulated by
incorporating selected excipients using model drug lamivudine.
Lamivudine, acetylated moth bean starch (AMBS), spray dried lac-
tose and PVP K-30 were dispensed accurately. Each ingredient was
shifted through #80 sieves, transferred in to a polyethylene bag and
mixed for 20 min. The slugs prepared were crushed into granules
and the mass was shifted through #20 sieves and weighed. The
quantity of remaining ingredients i.e.  magnesium stearate and talc
required for tablets was  calculated as per the formula to compen-
sate any loss during the direct compression process. The lubricated
dry powder was  compressed into tablets at 8 kg/cm2 pressure by
using 10 mm standard concave and ﬂat punch set in 10 station
rotary tablet punching machine. The tablets were double wrapped
in polyethylene bag till further study.
2.6. Evaluation of tabletsThe tablets from each batch were picked randomly in order to
evaluate the weight variation, the hardness, % of drug content and
the friability [11]. The hardness and friability of the tablet were
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marized in Table 1. DSC thermogram of LAM showed a sharp
endothermic peak at 182.73 ◦C corresponding to its melting point.
The endothermic peak of the drug was  well retained in majority of64 A.V. Singh, L.K. Nath / International Journal 
easured using Monsanto hardness tester and Roche friabilator
espectively.
.7. In vitro dissolution rate study
In vitro dissolution rate study of the formulations (n = 6) was
arried out in USP Type-II dissolution rate test apparatus. Disso-
ution rate study was performed in simulated gastric ﬂuid (0.1 M
Cl) and in simulated intestinal ﬂuid (PBS pH 6.8) for ﬁrst two
ours and for successive 10 h respectively. The each dissolution
edium (900 mL)  was maintained at 37 ± 0.5 ◦C throughout the
tudy. The samples (5 mL)  were withdrawn at predetermined time
1, 2, 3, 4, 6, 10, and 12 h) and replaced with an equivalent volume of
resh medium. The samples were ﬁltered through membrane ﬁlter
0.45 m)  and analysed by UV–Vis spectrophotometer at 270 nm
max). The cumulative percent drug release was plotted against
ime to determine the release proﬁle.
.8. Kinetics of drug release
The kinetics of drug release [12–15] is important because it
s a useful tool to correlate the in vitro drug release and in vivo
rug responses or to compare the results of pharmacokinetics with
issolution proﬁles of the formulations. Different mathematical
odels i.e.  zero order, ﬁrst order, Higuchi and Korsemeyer–Peppas
quations were applied for describing the kinetics of the drug
elease process from controlled released tablets of AMBS, the most
uited being the one which ﬁtted best in the experimental results.
.9. Pharmacokinetic study
The pharmacokinetic study of optimized controlled release
ablet (F7) of lamivudine was carried out in two  groups of three
ale white albino rabbits each weighing 1.5–2.5 kg. All animals
ere fasted overnight (12 h) before dosing and continued till 4.0 h
fter administration of tablets, thereafter rabbit chew diet was  pro-
ided ad libitum. Drinking water was deprived of before dosing and
ontinued till two hours of post dose, thereafter it was provided ad
ibitum. The tablets (n = 3) of batch, F7 were administered orally to
hree rabbits of each group along with 10 mL  of water by using feed-
ng tube. This study was approved by the Animal Ethical Committee
f Gayatri College of Pharmacy (Regn. No.1339/ac/10/cpcsea).
The blood samples each of about 50 L from each animal
ere collected from orbital sinus into the microcentrifuge tubes
ontaining 50 L of 10% (w/w) of disodium EDTA as anticoagu-
ant according to the sampling schedule (Pre dose, 0.25, 0.5, 1.0,
.0, 3.0, 4.0, 6.0, 9.0, 12.0 and 24.0 h). The collected blood sam-
les were centrifuged immediately at 1000 × g for 10 min. The
upernatent plasma layer was separated and stored at −20 ◦C till
nalysis.
.9.1. Plasma sample analysis
The 200 L of each sample was taken into 2 mL  centrifuge tube
nd 50 L of nelﬁnavir solution (50 g/mL) was added as an inter-
al standard (IS). The mixtures were vortexed for 10 s. Acetonitrile
1.5 mL)  was added into the mixture, vortexed for 3 min and cen-
rifuged at 10,000 rpm for 10 min. The supernatent was transferred
nto a glass centrifuge tube and evaporated to dryness at 45 ◦C
nder a stream of nitrogen. The residue was reconstituted with
00 L of reconstitution solvent (mobile phase). The samples were
ltered through 0.45 m membrane ﬁlter using syringe ﬁlter. An
liquot of 20 L of the sample was injected into the injector of the
PLC system. The samples were analysed by using the chromato-
raphic condition developed in the laboratory [16]. The area under
he curve of peaks of LAM and IS was determined and the con-
entration of drug present in sample was estimated by using theogical Macromolecules 50 (2012) 362– 368
linear regression equation of standard calibration curve (concen-
tration of LAM vs. ratio of LAM to IS). The amount of drug present in
200 L of plasma [(quantity obtained from linear regression equa-
tion/20) × 1000)] was  calculated [16–18].
2.9.2. Determination of pharmacokinetic parameters
The pharmacokinetic parameters were determined from the
data of plasma drug concentration at different time points by using
MS-Excel 2003 Software according to the procedure described else-
where [16–18].
2.10. Stability study
Stability study is used to assess expiration dating and stor-
age conditions for pharmaceutical products. Stability study of
lamivudine controlled release tablets were performed as per ICH
guideline. The optimized controlled release tablets were kept in
polypropylene bottle and stored in a stability chambers maintained
at 40 ± 2 ◦C and 75 ± 5% RH for six months. Samples were checked
initially, after three months and further after six months.
3. Results and discussion
3.1. Synthesis of highly substituted acetylated moth bean starch
The starch acetate with high degree of substitution (DS = 2.35)
was synthesized using pyridine as organic solvent. The optimized
temperature for synthesizing highly substituted starch was  found
to be 100 ◦C. The reaction duration for synthesizing highest sub-
stitution was  found to be 4 h, increasing the duration caused the
starch granule destruction which restricts acetylation of moth bean
starch. The preliminary degree of substitution was done by trimet-
ric analysis and it was  found to be 2.35.
3.2. Acute toxicity study
The purpose of this study was  to evaluate toxicity proﬁle of the
modiﬁed starch. A 14-day acute oral toxicity study was performed
in swiss albino mice. The LD50 of the modiﬁed starch (acetylated)
was not further studied as it was found to be safe up to 2000 mg/kg
on 24 h study basis. It was  observed that the animal fed with the
modiﬁed starch was  found healthy. No unusual changes in behav-
ior, or in locomotor activity, ataxia, and signs of toxicity were
observed during the 14 days period. No difference was found in
growth behavior between the control and treatment groups in 14-
day study. The body weights of male and female swiss albino mice
were found to be normal after treatment. There was  no change
observed in body weight of control and modiﬁed starch treated
mice.
3.3. Preformulation study
3.3.1. Drug–excipient compatibility study by DSC
DSC thermograms of drug and drug–excipient mixtures with
their corresponding peak temperatures and enthalpy values (H)
of lamivudine (LAM) with various excipient mixtures are sum-cases. However, in some combinations there were slight changes
in peak temperature and peak shape, which might be due to reduc-
tion of the purity level of component in mixtures, on mixing of
excipients with the drug.
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Table  1
Corresponding peak temperatures and enthalpy values of lamivudine in various drug–excipient mixtures in DSC study.
Sample Ratio (drug:excipient) Tonset (◦C) Tpeak (◦C) H (J g−1)
LAM – 177 40 182 73 74 54
LAM  + AMBS 1:1 177.58 183.79 101.76
LAM  + PVP K-30 1:1 174.32 180.09 72.43
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3.7. Kinetics and mechanism of drug release
The release rate constant was  calculated from the slope of
the appropriate equations and the correlation coefﬁcient (R) wasLAM  + SDL 1:1 
LAM  + Magnesium stearate 1:1 
LAM  + Talc 1:1 
.3.2. FT-IR analysis of drug–excipients mixture
Pure lamivudine showed the characteristic band peaks at
651.12 cm−1 which corresponds to cystedine nucleus. A charac-
eristic bands peak at 3407.58 and 3198.77 cm−1 represents the
mino and hydroxy groups present in lamivudine. Peaks present at
287.37 and 1160.32 cm−1 represents the asymmetrical and sym-
etrical stretching of C O C group present in oxathiolane ring of
amivudine. All the binary mixtures of drug and excipient showed
one type of physical interaction except with magnesium stearate.
n FT-IR spectral diagram of drug-magnesium stearate there is
ntroduction of absorption bands at 2955.18 and 2850.32 cm−1,
hich might be a type of physical interaction, but in thermal anal-
sis (DSC and IST) there was no conﬁrmation for the same.
.3.3. Isothermal stress testing study
In the isothermal stress testing, drug–excipient binary mixtures
howed no change in physical appearance at ambient temperature.
he blends remain physically stable and no discoloration, lique-
action or gas formation was observed during storage. There was
o signiﬁcant drug degradation observed in the excipients. Table 2
hows percent of drug remaining at the end of the study at 50 ◦C.
.4. Formulation of controlled release tablets
The formulae of the lamivudine (LAM) controlled release tablets
ave been depicted in Table 3. Spray dried lactose was selected as
irect compression diluent by considering its advantages in terms
f good compressibility, easy availability, cost effectiveness and low
oisture sensitivity. PVP K-30 was used as dry binder considering
ts widespread applicability in industry and relatively low moisture
ensitivity. Magnesium stearate and talc were used as lubricant
nd glidant respectively due to their widespread applicability in
ndustry and relative moisture insensitivity. Highly substituted
cetylated moth bean starch (AMBS) was used as hydrophobic poly-
eric carrier material for the production of LAM oral controlled
elease tablet. The batches (F1–F8) of tablets were prepared to
elect the suitable grades of AMBS. The tablets were formulated
o attain 8 kg/cm2 hardness with varying concentration of AMBS
25–200 mg/tablet). The tablets were formulated without any pro-
essing difﬁculties (stickiness, lamination, capping and picking).
.5. Evaluation of physical parameters of tablets
.5.1. General appearance and thickness
The tablets of all the batches were white in color, ﬂat, round
haped and plane from both sides. The thickness (4.61 ± 1.1 mm to
.62 ± 1.4 mm)  of all the batches of tablets is shown in Table 4..5.2. Weight variation
The average weight of 20 tablets along with standard deviation
f entire formulations has been presented in Table 4. The per-
entage of weight variation of individual tablets from the average
eight was found to be within ±5% (w/w) which proved that the
ntire tablets have passed the USP weight variation test.171.56 179.44 48.78
177.63 182.91 80.66
178.64 183.32 98.38
3.5.3. Drug content
The drug content of all the tablets in each batch was found to be
in the range of 99.98 ± 1.4% to 103 ± 1.6% which is shown in Table 4.
The results indicated that tablets of entire batches have passed the
USP criteria for the drug content of tablets.
3.5.4. Hardness
The hardness of tablets of entire batches was  found to be in
the range of 8.1 ± 1.4 kg/cm2 to 8.3 ± 2.1 kg/cm2 and the results are
depicted in Table 4.
3.5.5. Friability
The results of the friability test of entire formulations are
depicted in Table 4. It was observed that the tablets of entire batches
had passed USP criteria of friability testing (<1.00%, w/w). The
results revealed that tablets possessed good mechanical strength.
3.6. In vitro drug release study
The comparative results (n = 6) of in vitro drug release study
of all the batches of tablets are shown in Fig. 1. From the drug
release proﬁle of the batches from F1 to F4 it is seen that the total
amount of drug was released within 6 h, while from the batches F5
and F6, the total amount of drug was released within 8 h. Release
proﬁle of F7 showed a superior ﬁt to the desired controlled drug
release proﬁle among all the batches. The tablets of batch F8 (with
highest concentration of AMBS) also showed a controlled release
pattern but signiﬁcantly a less amount of drug was  released from
them so, batch F8 was  not considered for further study. The result
of drug release proﬁle of the batch F7 showed the release of 28%
(w/w) of drug during initial 2 h, while within the ﬁrst 6 h 68% of
drug was released and the remaining 32% (w/w)  of the drug was
released within the remaining 6 h. Hence, a controlled release pat-
tern of drug was observed from the batch F7 throughout the 12 h
of dissolution study.Fig. 1. In vitro dissolution rate proﬁle of all the batches of tablets.
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Table  2
Results of UV analysis of the drug–excipient mixtures, under isothermal stress testing after 4 weeks of storage.
Sample Ratio (drug:excipient) % Drug remaininga Change in physical appearance
Controlb sample Stressedc sample
LAM – 101.12 ± 3.2 99.97 ± 3.1 No
LAM  + AMBS 1:2 103.36 ± 2.5 101.12 ± 1.6 No
LAM  + SDL 1:2 102.51 ± 2.1 102.34 ± 0.7 No
LAM  + PVP 1:1 103.67 ± 2.2 101.87 ± 1.1 No
LAM  + Magnesium Steanate 1:1 101.45 ± 1.5 100.12 ± 2.2 No
LAM  + Talc 1:1 101.22 ± 4.1 100.02 ± 1.1 No
a Values expressed as average ± standard deviation (n = 3).
b Drug excipient blends without added water and stored in refrigerator.
c Drug excipient blends with 10% added water and stored at 50 ◦C for 4 weeks.
Table 3
Composition of lamivudine controlled release tablet using AMBS.
Ingredients (mg) Formulation code
F1 F2 F3 F4 F5 F6 F7 F8
Lamivudine 100 100 100 100 100 100 100 100
Acetylated moth bean starch 25 50 75 100 125 150 175 200
PVP  K-30 20 20 20 20 20 20 20 20
Spray  dried lactose q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s.
Magnesium stearate 4 4 4 4 4 4 4 4
Talc  4 4 4 4 4 4 4 4
Total  weight 400 400 400 400 400 400 400 400
q.s., quantity sufﬁcient.
Table 4
Physical properties of lamivudine CR tablets using AMBS as release retardant.
Batches Drug content (%) Weight deviation (%) Hardness (kg/cm2) Friability (%) Thickness (mm)
F1 101.2 ± 2.1 402 ± 1.4 8.1 ± 1.4 0.65 ± 1.3 4.66 ± 0.5
F2  99.98 ± 1.4 398 ± 0.8 8.3 ± 1.7 0.45 ± 1.7 4.65 ± 1.2
F3 100.56 ±  1.3 403 ± 1.2 8.2 ± 2.1 0.43 ± 1.1 4.67 ± 1.4
F4  102.12 ± 0.9 405 ± 1.7 8.3 ± 2.0 0.34 ± 1.7 4.66 ± 2.1
F5 101.6  ± 1.2 401 ± 1.4 8.2 ± 1.3 0.36 ± 1.5 4.63 ± 2.2
F6  99.98 ± 1.4 397 ± 1.1 8.2 ± 1.1 0.29 ± 1.4 4.61 ± 1.1
F7  103.1 ± 1.6 409 ± 2.1 8.3 ± 2.1 0.27 ± 1.2 4.62 ± 1.8
A
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CF8  101.2 ± 1.5 401 ± 1.5 
ll values represent mean ± standard deviation (n = 3).
etermined for all formulations (Table 5). The in vitro drug release
f optimized batch (F7) was best ﬁtted and explained by Higuchi
inetics with the highest linearity (RH = 0.981), followed by zero
rder (Ro = 0.9619) and ﬁrst order (RF = 0.896). This explains that
atch F7 was found to be best ﬁtted in Higuchi kinetics as compared
o other batches. All other batches showed neither good (high)
orrelation value (R) nor acceptable K value (low). This explains
hat the drug release from monolithic matrix tablet prepared with
MBS with highest DS value followed primarily diffusion controlled
echanism. The model drug LAM was assumed to be diffused
nly through the pores that were formed by dissolution of dis-
ersed drug particles i.e.  the drug release mechanism was  leaching
able 5
omparative release kinetics parameter of all batches of tablets.
Formulation code Release kinetic parameters
Zero order First order 
RO KO Rf
F1 0.8611 25.2 0.9238 −
F2  0.8978 19.9 0.9601 −
F3  0.8909 16.6 0.9531 −
F4  0.9136 14.11 0.9549 −
F5  0.9159 12.46 0.9561 −
F6 0.9197  9.9 0.9115 −
F7  0.9619 8.08 0.896 −
F8 0.9589  6.42 0.9991 −8.2 ± 1.9 0.26 ± 0.21 4.64 ± 1.4
of dissolved drugs through the pores. Inter-particulate porosity is
essential for solvent penetration into the monolithic matrix and
consequently for drug release. The drug release mechanism from
controlled release devices is very complex to explain and still
not yet completely understood. Although some controlled release
processes may  be classiﬁed as either purely diffusional or purely
erosion controlled and many others can only be interpreted as being
governed by both the mechanism. To evaluate the in vitro drug
release proﬁle, the data at various time points were ﬁtted into the
Korsemayer–Peppas equation, where Kp is the release rate constant
and np is characteristics for the mechanism of the drug release. With
an np value of 0.5, the equation becomes equal to the square root of
Higuchi Korsemeyer & Peppas
Kf Rh Kh Rp np
0.57 0.9616 53.86 0.8896 0.591
0.42 0.9764 8.03 0.9566 0.624
0.32 0.9674 4.47 0.9536 0.657
0.29 0.9784 1.14 0.9748 0.653
0.25 0.9723 9.16 0.972 0.702
0.20 0.9753 5.43 0.9771 0.701
0.15 0.9813 1.98 0.995 0.719
0.05 0.9782 5.29 0.992 0.762
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Table  6
Pharmacokinetic parameters of marketed and optimized lamivudine controlled release tablet (F7) after a single oral dose of 100 mg lamivudine to rabbits (n = 3).
Pharmacokinetic parameters Observed value (Lamivir®) Observed value (F7)
Maximum plasma concentration, Cmax (ng/mL) 12,784.91 ± 2.1 8342.56 ± 3.4
Time  required to reach maximum plasma concentration, Tmax (h) 1.00 ± 1.6 4.00 ± 2.2
Area  under curve at 24 h, AUC(0 → ∞) (ng h/mL) 54,206.284 ± 3.7 57,075.323 ± 4.5
Area  under momentum curve at 24 h, AUMC(0 → ∞) (ng h2/mL) 227,067.968 ± 0.6 306,847.633 ± 1.2
Volume  of distribution, Vd (L) 9.574 ± 2.8 16.910 ± 3.1
Plasma  half life, T1/2 (h) 3.594 ± 0.2 6.690 ± 4.1
Absorption rate constant, Ka (h−1) 2.142 ± 1.8 0.796 ± 1.0
−1 0.193 ± 1.5 0.105 ± 2.4
4.189 ± 2.1 5.376 ± 2.1
1.846 ± 3.0 1.753 ± 1.7
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odel described by Higuchi, which signiﬁes that drug release from
he matrix is governed by Fickian diffusion, for np > 0.5, anomalous
on-Fickian drug diffusion occurs i.e. combination of both diffu-
ion or swelling and erosion mechanism takes place. For np > 1,
on-Fickian case-II, erosion controlled or zero order release kinet-
cs is followed. The Rp and np values of various batches of tablets
re presented in Table 5. The Rp values of 0.8896, 0.9566, 0.9536,
.9748, 0.972, 0.9771, 0.995 and 0.992 for the tablets F1, F2, F3,
4, F5, F6, F7 and F8 respectively indicated good linearity between
og cumulative amount of drug release and log time. The Rp value
f all the tablets was found to be linear and highest linearity was
bserved with the batch F7, where the concentration of AMBS as
elease retardant polymer was quite high. The value of np was 0.591,
.624, 0.657, 0.653, 0.702, 0.701, 0.719 and 0.762 for the batches
f tablets F1, F2, F3, F4, F5, F6, F7 and F8 respectively. Hence, the
echanism of drug release from the tablets was predicted from
orsemayer–Peppas equations and from the obtained np values of
ll the batches of tablets (np > 0.5) it is revealed that the mechanism
f drug release was a coupling of both the process of diffusion and
rosion.
.8. In vivo pharmacokinetics
The results of the plasma drug concentration at different time
ntervals, after administration of controlled release tablets con-
aining 100 mg  of lamivudine to three rabbits, are presented in
able 6. The drug was remained in the body of the animals up to
4 h of administration of the tablet. The comparison of the differ-
nt parameters was done by using a one-way analysis of variance
ANOVA). A value of p < 0.05 was considered statistically signiﬁ-
ant. The pharmacokinetic parameters were derived from plasma
rug concentrations versus time proﬁle of all the subjects and
he results are shown in Table 6. The Tmax of controlled release
ablets was found to be 4 h, as compared to 1.0 h for the mar-
eted conventional tablet (Lamivir®), which indicates the slow
bsorption rate from the CR tablet due to extended release effect
f hydrophobic polymer present in controlled release tablets. The
verage Cmax value of the controlled release tablets was decreased
s compared to conventional tablets (from 12,784.91 ± 2.1 ng/mL
o 8342.56 ± 3.4 ng/mL). The AUC0–∞ of controlled release tablets
f lamivudine exhibited high value (57,075.323 ± 4.5 ng h/mL) as
ompared to conventional tablets (54,206.284 ± 3.7 ng h/mL). The
UMC0–∞ of controlled release tablets was found to be higher
06847.63 ± 1.2 ng h2/mL  as compared to the low value of con-
entional tablets (227067.96 ± 0.6 ng h2/mL). The mean Vd and
learance values for controlled release tablets were found to be
6.91 ± 3.1 and 1.753 ± 1.7 L/h respectively. The Ka and Ke value
or controlled release tablets was found to be 0.796 ± 1.0 and
.105 ± 2.4 h−1 which is lower than the values of the conventional
ablets. The mean residence time (MRT) of controlled release tablets
as found to be higher (5.376 ± 2.1 h) than that of the conventional
ablets (4.189 ± 2.1 h) conﬁrming the controlled release property
f the modiﬁed starch AMBS. The results revealed that the drugFig. 2. Comparative in vivo pharmacokinetic study of marketed conventional tablet
of  Lamivir® and optimized formulation (F7).
was made available to the body in a controlled release manner
and the controlled release effect was due to the presence of higher
proportion of AMBS in the tablets as evident from Fig. 2.
3.9. Stability study
The selected optimized formulation (F7) was  evaluated for var-
ious parameters (drug content, dissolution study) after 3 and 6
months of storage at accelerated stability conditions (40 ± 2 ◦C and
75 ± 5% RH). There was no signiﬁcant amount of change observed in
the drug content of tablets after 6 months of storage at accelerated
stability conditions. The dissolution proﬁle of formulation at initial
stage was considered as the reference for dissolution study. The
results obtained revealed that the dissolution proﬁle of the formu-
lation after 6 months of storage at accelerated condition was found
to be similar to that of reference one. Based on the results it was
opinioned that the tablets of batch F7 was stable after 6 months of
storage at accelerated stability conditions.
4. Conclusion
The present study focused on the formulation of 12 h con-
trolled release tablets of lamivudine using AMBS as matrix forming
hydrophobic polymer. It was summarized from the dissolution
study of the entire batches that the tablets contain less concen-
tration of AMBS were disintegrated with in 1.0 h and unable to
control the release of drug. At higher concentration of AMBS the
tablets released the drug in controlled release manner over 12 h
study. The study of release mechanism exhibited anomalous non-
Fickian diffusion which involved combination of both diffusion and
erosion mechanism. The pharmacokinetic study of the optimized
batch of formulation (F7) in rabbits was  carried out in replicate.
The plasma drug concentration versus time interval was  estimated
by using in house developed RP-HPLC method. The optimized con-
trolled release tablets exhibited ﬁrst order rate kinetics in release
of drug from the tablets. The increase in Tmax value and decrease in
Cmax value in case of the optimized formulation F7 from the values
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